249420 — Il Dong Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩331bn
- KR₩471bn
- KR₩615bn
- 36
- 31
- 45
- 28
Annual income statement for Il Dong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 561,845 | 560,132 | 637,714 | 600,758 | 614,941 |
| Cost of Revenue | |||||
| Gross Profit | 238,414 | 219,439 | 236,343 | 213,846 | 233,459 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 563,140 | 616,701 | 729,469 | 657,662 | 613,791 |
| Operating Profit | -1,295 | -56,569 | -91,754 | -56,904 | 1,150 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9,724 | -141,205 | -119,823 | -94,273 | -10,692 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13,019 | -100,968 | -142,170 | -80,961 | -12,402 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -13,019 | -99,705 | -141,585 | -78,928 | -4,576 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13,019 | -99,705 | -141,585 | -78,928 | -4,576 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -386 | -4,161 | -4,917 | -2,876 | 229 |
| Dividends per Share |